Get the Stockscreener App
2.66
0.00%
0.00
After Hours:
2.69
0.03
+1.13%
Organogenesis Holdings Inc stock is traded at $2.66, with a volume of 487.77K.
It is up +0.00% in the last 24 hours and up +10.37% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$2.66
Open:
$2.65
24h Volume:
487.77K
Relative Volume:
0.35
Market Cap:
$342.27M
Revenue:
$564.17M
Net Income/Loss:
$37.03M
P/E Ratio:
24.29
EPS:
0.1095
Net Cash Flow:
$-24.46M
1W Performance:
+10.37%
1M Performance:
+10.37%
6M Performance:
-52.42%
1Y Performance:
-10.44%
1-Day Range:
$2.605
$2.69
1-Week Range:
$2.38
$2.69
52-Week Range:
$2.04
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.66 | 342.27M | 564.17M | 37.03M | -24.46M | 0.1095 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook - MSN
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings stock (US68620V1026): FDA warning letter and Nasdaq notice put focus on compl - AD HOC NEWS
Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update - AD HOC NEWS
Organogenesis Holdings Inc.Class A (NQ: ORGO - FinancialContent
Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS - AD HOC NEWS
TradingKey - tradingkey.com
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2026 Earnings Call Transcript - Insider Monkey
RI skin-maker Organogenesis reports steep Q1 loss amid CMS policy change - The Business Journals
Organogenesis (ORGO) Q1 2026 Earnings Transcript - AOL.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds By Investing.com - Investing.com South Africa
BTIG Downgrades Organogenesis(ORGO.US) to Hold Rating - Moomoo
Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery - MSN
symbol__ Stock Quote Price and Forecast - CNN
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Organogenesis Q1 Earnings Call Highlights - Barchart.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Report: Exploring A Potential 216% Upside - DirectorsTalk Interviews
Skin Substitute Market Is Going to Boom Rapidly |Organogenesis - openPR.com
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts By Investing.com - Investing.com South Africa
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts - Investing.com Australia
Organogenesis : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Organogenesis Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Organogenesis: Q1 Earnings Snapshot - Barchart.com
ORGO: Revenue fell 58% and net loss widened sharply in Q1 2026 amid regulatory disruption - TradingView
Organogenesis posts $53M loss as wound-care sales drop 63% - Stock Titan
[10-Q] Organogenesis Holdings Inc. Quarterly Earnings Report - Stock Titan
Organogenesis (NASDAQ: ORGO) posts 58% Q1 revenue drop and deeper loss - Stock Titan
Credit Suisse reiterated coverage on Organogenesis Holdings with a new price target - Quantisnow
U.S. Perinatal Tissue-derived Allograft Market Detailed In New - openPR.com
ORGO Price Today: Organogenesis Holdings Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
[ARS] Organogenesis Holdings Inc. SEC Filing - Stock Titan
Organogenesis (NASDAQ: ORGO) details 2026 virtual meeting, pay and audit votes - Stock Titan
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® - Orthopedics This Week
Organogenesis (ORGO) Projected to Post Earnings on Thursday - MarketBeat
Organogenesis completes biologics license application for knee OA By Investing.com - Investing.com India
Organogenesis completes biologics license application for knee OA - Investing.com UK
Organogenesis Holdings Inc. Completes Biologics License Application Submission for ReNu® to Treat Knee Osteoarthritis - Quiver Quantitative
What's going on with Organogenesis stock on Wednesday? - MSN
Organogenesis (NASDAQ:ORGO) Trading Up 1.7%Time to Buy? - MarketBeat
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):